安慰剂-话题@MedSci

#安慰剂#

133篇内容 | 3525人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1304403, encodeId=45bd1304403d2, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=61, createdTime=2021-06-28, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304402, encodeId=643d130440277, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), objectType=article, longId=212511, objectId=4d8b21251198, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8b21251198, replyNumber=0, likeNumber=42, createdTime=2021-06-11, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8b21251198, moduleTitle=JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8b21251198)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304401, encodeId=ab7a130440116, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , objectType=article, longId=212089, objectId=fc5c2120893c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5c2120893c, replyNumber=0, likeNumber=57, createdTime=2021-06-01, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5c2120893c, moduleTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5c2120893c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304400, encodeId=38eb130440046, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Ferring和Rebiotix呈报的标志性3期数据显示，在研RBX2660减少艰难梭菌反复感染的有效性优于安慰剂, objectType=article, longId=211818, objectId=768c211818c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768c211818c9, replyNumber=0, likeNumber=86, createdTime=2021-05-27, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768c211818c9, moduleTitle=Ferring和Rebiotix呈报的标志性3期数据显示，在研RBX2660减少艰难梭菌反复感染的有效性优于安慰剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=768c211818c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304399, encodeId=98b61304399a1, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：预后不良的吉兰-巴雷综合征（SID-GBS）患者的第二次静脉注射免疫球蛋白：一项双盲、随机、安慰剂对照试验 , objectType=article, longId=209626, objectId=dbf9209626d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbf9209626d6, replyNumber=0, likeNumber=40, createdTime=2021-04-08, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbf9209626d6, moduleTitle=Lancet Neurology：预后不良的吉兰-巴雷综合征（SID-GBS）患者的第二次静脉注射免疫球蛋白：一项双盲、随机、安慰剂对照试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbf9209626d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304398, encodeId=86671304398a5, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, objectType=article, longId=208701, objectId=790a208e01b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=790a208e01b0, replyNumber=0, likeNumber=85, createdTime=2021-03-21, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=790a208e01b0, moduleTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=790a208e01b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304397, encodeId=9ac8130439e65, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：替拉奈单抗治疗进行性核上性麻痹的安全性和有效性:一项2期随机安慰剂对照试验 , objectType=article, longId=208288, objectId=091e208288b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=091e208288b0, replyNumber=0, likeNumber=56, createdTime=2021-03-13, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=091e208288b0, moduleTitle=Lancet Neurology：替拉奈单抗治疗进行性核上性麻痹的安全性和有效性:一项2期随机安慰剂对照试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091e208288b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304396, encodeId=7259130439672, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Nat Commun：安慰剂镇痛相关大脑神经系统活动的荟萃分析研究, objectType=article, longId=207932, objectId=2b2420e93209, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2420e93209, replyNumber=0, likeNumber=0, createdTime=2021-03-07, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2420e93209, moduleTitle=Nat Commun：安慰剂镇痛相关大脑神经系统活动的荟萃分析研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2420e93209)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304395, encodeId=5c461304395ce, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：利鲁唑治疗退行性颈椎病减压手术患者的安全性和有效性：一项多中心、双盲、安慰剂对照、随机、3期试验 , objectType=article, longId=207349, objectId=a3c320e349ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c320e349ac, replyNumber=0, likeNumber=74, createdTime=2021-02-21, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c320e349ac, moduleTitle=Lancet Neurology：利鲁唑治疗退行性颈椎病减压手术患者的安全性和有效性：一项多中心、双盲、安慰剂对照、随机、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3c320e349ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304394, encodeId=b29e130439453, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Nat Commun：安慰剂对照试验：粪便微生物群移植治疗HIV, objectType=article, longId=207332, objectId=4e7f20e3329e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e7f20e3329e, replyNumber=0, likeNumber=78, createdTime=2021-02-21, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e7f20e3329e, moduleTitle=Nat Commun：安慰剂对照试验：粪便微生物群移植治疗HIV, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e7f20e3329e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304393, encodeId=46601304393c4, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：泼尼松与安慰剂短期预防阵发性丛集性头痛的安全性和有效性：一项多中心、双盲、随机对照试验 , objectType=article, longId=205525, objectId=370820552554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=370820552554, replyNumber=0, likeNumber=70, createdTime=2021-01-10, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=370820552554, moduleTitle=Lancet Neurology：泼尼松与安慰剂短期预防阵发性丛集性头痛的安全性和有效性：一项多中心、双盲、随机对照试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=370820552554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304392, encodeId=ec1b1304392d4, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=干细胞疗法治疗重症COVID-19患者：双盲安慰剂对照试验已证明JadiCells的有效性, objectType=article, longId=205446, objectId=eece205446a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eece205446a7, replyNumber=0, likeNumber=44, createdTime=2021-01-09, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eece205446a7, moduleTitle=干细胞疗法治疗重症COVID-19患者：双盲安慰剂对照试验已证明JadiCells的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eece205446a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304391, encodeId=15f7130439142, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究, objectType=article, longId=204949, objectId=3e49204949d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e49204949d8, replyNumber=0, likeNumber=49, createdTime=2020-12-30, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e49204949d8, moduleTitle=患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e49204949d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304390, encodeId=efd313043904d, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究, objectType=article, longId=204834, objectId=996020483414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=996020483414, replyNumber=0, likeNumber=80, createdTime=2020-12-25, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=996020483414, moduleTitle=患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=996020483414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304389, encodeId=5aca1304389ba, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验, objectType=article, longId=204612, objectId=b76e204612db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b76e204612db, replyNumber=0, likeNumber=47, createdTime=2020-12-18, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b76e204612db, moduleTitle=Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b76e204612db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304388, encodeId=ae86130438852, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：氨甲环酸在脑出血患者中的应用（STOP-AUST）: 一项多中心、随机、安慰剂对照的2期试验 , objectType=article, longId=204291, objectId=3635204291af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3635204291af, replyNumber=0, likeNumber=65, createdTime=2020-12-09, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3635204291af, moduleTitle=Lancet Neurology：氨甲环酸在脑出血患者中的应用（STOP-AUST）: 一项多中心、随机、安慰剂对照的2期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3635204291af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304387, encodeId=1a40130438e56, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：氟西汀对急性脑卒中后功能预后的安全性和有效性（AFFINITY）：一项随机、双盲、安慰剂对照试验, objectType=article, longId=203722, objectId=ccd2203e2294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd2203e2294, replyNumber=0, likeNumber=37, createdTime=2020-11-26, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd2203e2294, moduleTitle=Lancet Neurology：氟西汀对急性脑卒中后功能预后的安全性和有效性（AFFINITY）：一项随机、双盲、安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccd2203e2294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304386, encodeId=0b2b1304386a5, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验, objectType=article, longId=202520, objectId=74bc20252090, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74bc20252090, replyNumber=0, likeNumber=70, createdTime=2020-10-27, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74bc20252090, moduleTitle=Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74bc20252090)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304385, encodeId=6064130438510, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=JNNP:拉考沙胺治疗辅助治疗原发性全身性强直-阵挛性癫痫的疗效和安全性：一项双盲，随机，安慰剂对照试验, objectType=article, longId=200658, objectId=72552006581b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72552006581b, replyNumber=0, likeNumber=0, createdTime=2020-09-15, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72552006581b, moduleTitle=JNNP:拉考沙胺治疗辅助治疗原发性全身性强直-阵挛性癫痫的疗效和安全性：一项双盲，随机，安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72552006581b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1304384, encodeId=1348130438484, content=<a href='/topic/show?id=81724580886' target=_blank style='color:#2F92EE;'>#安慰剂#</a>, objectTitle=JNNP：拉康酰胺辅助治疗原发性全身强直阵挛性癫痫的疗效和安全性：一项双盲、随机、安慰剂对照试验, objectType=article, longId=199805, objectId=d3371998058f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3371998058f, replyNumber=0, likeNumber=0, createdTime=2020-08-23, rootId=0, userName=wleon8895, userId=4cce318, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3371998058f, moduleTitle=JNNP：拉康酰胺辅助治疗原发性全身强直阵挛性癫痫的疗效和安全性：一项双盲、随机、安慰剂对照试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3371998058f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

安慰剂

2020-05-29

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-06-28

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

JCO：阿替利珠单抗（Atezolizumab）+贝伐珠单抗+化疗在初始诊断III或IV期卵巢癌中的疗效和安全性：安慰剂对照随机III期研究(IMagyn050/GOG 3015/ENGOT-OV39)

2021-06-11

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验

2021-06-01

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Ferring和Rebiotix呈报的标志性3期数据显示，在研RBX2660减少艰难梭菌反复感染的有效性优于安慰剂

2021-05-27

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：预后不良的吉兰-巴雷综合征（SID-GBS）患者的第二次静脉注射免疫球蛋白：一项双盲、随机、安慰剂对照试验

2021-04-08

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！

2021-03-21

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：替拉奈单抗治疗进行性核上性麻痹的安全性和有效性:一项2期随机安慰剂对照试验

2021-03-13

智者为医08 (审核中...)

前往app查看评论内容

#安慰剂#

Nat Commun：安慰剂镇痛相关大脑神经系统活动的荟萃分析研究

2021-03-07

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：利鲁唑治疗退行性颈椎病减压手术患者的安全性和有效性：一项多中心、双盲、安慰剂对照、随机、3期试验

2021-02-21

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Nat Commun：安慰剂对照试验：粪便微生物群移植治疗HIV

2021-02-21

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：泼尼松与安慰剂短期预防阵发性丛集性头痛的安全性和有效性：一项多中心、双盲、随机对照试验

2021-01-10

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

干细胞疗法治疗重症COVID-19患者：双盲安慰剂对照试验已证明JadiCells的有效性

2021-01-09

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

患者招募：Pamrevlumab或安慰剂联合吉西他滨/白蛋白紫杉醇（G/N）作为新辅助治疗用于局部晚期不可切除胰腺癌：一项III期、随机、双盲研究

2020-12-30

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

患者招募：卡瑞利珠单抗联合法米替尼或安慰剂与化疗治疗非小细胞肺癌患者的随机、双盲、对照、多中心临床研究

2020-12-25

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：Satralizumab单药治疗视神经脊髓炎谱系障碍的安全性和有效性：一项随机、双盲、多中心、安慰剂对照的3期试验

2020-12-18

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：氨甲环酸在脑出血患者中的应用（STOP-AUST）: 一项多中心、随机、安慰剂对照的2期试验

2020-12-09

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：氟西汀对急性脑卒中后功能预后的安全性和有效性（AFFINITY）：一项随机、双盲、安慰剂对照试验

2020-11-26

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

Lancet Neurology：Galcanezumab对既往2-4类偏头痛预防药物治疗失败的患者的安全性和有效性(CONQUER)：一项多中心、随机、双盲、安慰剂对照的3b期试验

2020-10-27

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

JNNP:拉考沙胺治疗辅助治疗原发性全身性强直-阵挛性癫痫的疗效和安全性：一项双盲，随机，安慰剂对照试验

2020-09-15

wleon8895 (审核中...)

前往app查看评论内容

#安慰剂#

JNNP：拉康酰胺辅助治疗原发性全身强直阵挛性癫痫的疗效和安全性：一项双盲、随机、安慰剂对照试验

2020-08-23

科室
- - 订阅+
  - 更多科室
工具
服务